Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.27 | $2M | -$4M |
| 2025 Q1 | -0.06 | $4M | -$7M |
| 2025 Q4 | -0.06 | $0 | -$6M |
| 2025 Q3 | -0.07 | $0 | $0 |
| 2025 Q2 | -0.11 | $0 | $0 |
| 2024 Q1 | -0.09 | $0 | $0 |
| 2024 Q4 |
| -0.10 |
| $0 |
| $900,289 |
| 2024 Q3 | -0.07 | $0 | -$364,060 |